Discovery Vitality adds doctor-led GLP-1 pathway to weight programme

Discovery Vitality has expanded its HealthyWeight programme to include a doctor-led pathway that may result in GLP-1 anti-obesity medicine prescriptions for eligible members, alongside dietitian coaching and behavioural support. The Johannesburg-based health insurer announced the move on 1 October 2026, accompanied by a white paper arguing that medication alone is insufficient to produce lasting results.

The company says members who meet the clinical criteria, broadly defined as a BMI of 30 or above, or a BMI of 27 or above with weight-related comorbidities, will receive an initial dietitian consultation, pathology tests and a GP appointment at no cost. Enrolment in the medicated pathway costs R295 per month.

The GLP-1 discontinuation problem

Discovery's internal data underline why the company has structured the programme around integrated support rather than medication alone. Members typically stop claiming for GLP-1 medicines within six months, a pattern consistent with broader real-world evidence showing that many patients discontinue treatment within a year. Discovery cites research suggesting roughly two-thirds of weight lost can be regained within a year of stopping medication, a finding that has become a central concern for payers and clinicians deploying this class of drug at scale.

Pilot data from the HealthyWeight medicated pathway offer an early signal that the combined approach may improve adherence to healthier behaviours. Participants increased healthy food purchases by 46%, reduced unhealthy food purchases by 25%, and improved achievement of weekly physical activity goals by 34%, according to Discovery. The company cautioned that these figures come from a pilot cohort rather than a randomised controlled trial, and the full methodology has not been published in a peer-reviewed journal.

Dr Mosima Mabunda, Chief Clinical Officer of Discovery Vitality, said the medicines had "redefined what is possible for people living with obesity" but that the key question was now how to help members sustain results. "Obesity is a chronic disease that requires long-term management. While medication can be highly effective, the greatest and most lasting health benefits come when it is paired with evidence-based nutrition, physical activity and behavioural support."

Affordability and market context

Discovery acknowledges that cost remains a material barrier to access. Its own health scheme, Discovery Health Medical Scheme, has previously stated that broader GLP-1 uptake will require significant price reductions and cross-sector collaboration on funding models. In a step toward reducing the effective cost of treatment, Discovery Corporate and Employee Benefits has introduced a reward scheme called WeightCare: Group Risk members enrolled in the medicated pathway can earn up to 10,000 Discovery Miles per month by hitting Vitality activity goals, which the company says can reduce the net cost of therapy by up to 50% for qualifying members.

The GLP-1 market has expanded rapidly in South Africa, with Discovery's own data showing a roughly threefold increase in member uptake since 2022. The class, which includes semaglutide and tirzepatide products approved in multiple markets, has drawn intense commercial interest from employers and insurers globally, particularly as real-world evidence accumulates on cardiometabolic outcomes beyond weight loss alone.

Discovery's move reflects a wider trend among private healthcare funders to condition GLP-1 coverage on structured lifestyle programmes, a model being tested by insurers in the United States and United Kingdom. Whether such integrated pathways can reduce long-term discontinuation rates at a population level remains an open question, and one the academic and payer communities are actively studying. The company's white paper, titled Beyond Medication, does not itself appear in a peer-reviewed publication, and the pilot behavioural data it presents will require independent validation before they can be treated as generalisable evidence.